Form 8-K - Current report:
SEC Accession No. 0001437749-21-006835
Filing Date
2021-03-23
Accepted
2021-03-23 06:01:23
Documents
8
Period of Report
2021-03-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K atos20210321_8k.htm 8-K 34780
2 EXHIBIT 1.1 SECURITIES PURCHASE AGREEMENT ex_235747.htm EX-1.1 327982
3 EXHIBIT 1.2 PLACEMENT AGENCY AGREEMENT ex_235748.htm EX-1.2 64945
4 EXHIBIT 1.3 FORM OF LOCK-UP AND VOTING AGREEMENT ex_235941.htm EX-1.3 19779
5 EXHIBIT 4.1 FORM OF COMMON STOCK PURCHASE WARRANT ex_235749.htm EX-4.1 81153
6 EXHIBIT 5.1 OPINION OF GIBSON, DUNN & CRUTCHER LLP ex_235750.htm EX-5.1 6990
7 gibsonlogo01.jpg GRAPHIC 11107
8 gobsonlogo02.jpg GRAPHIC 10072
  Complete submission text file 0001437749-21-006835.txt   565830
Mailing Address 107 SPRING STREET SEATTLE WA 98104
Business Address 107 SPRING STREET SEATTLE WA 98104 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35610 | Film No.: 21763041
SIC: 2834 Pharmaceutical Preparations